United Capital Financial Advisers LLC Decreases Stake in Stryker Corporation (SYK)

United Capital Financial Advisers LLC lowered its position in shares of Stryker Corporation (NYSE:SYK) by 13.5% during the first quarter, according to its most recent filing with the SEC. The firm owned 27,295 shares of the medical technology company’s stock after selling 4,244 shares during the period. United Capital Financial Advisers LLC’s holdings in Stryker Corporation were worth $3,593,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the stock. Teachers Advisors LLC boosted its position in Stryker Corporation by 5.7% in the fourth quarter. Teachers Advisors LLC now owns 377,336 shares of the medical technology company’s stock valued at $45,209,000 after buying an additional 20,450 shares during the last quarter. Macquarie Group Ltd. boosted its position in Stryker Corporation by 13.3% in the fourth quarter. Macquarie Group Ltd. now owns 103,000 shares of the medical technology company’s stock valued at $12,341,000 after buying an additional 12,100 shares during the last quarter. Pensionfund Sabic purchased a new position in Stryker Corporation during the first quarter valued at $2,014,000. Toth Financial Advisory Corp boosted its position in Stryker Corporation by 0.6% in the first quarter. Toth Financial Advisory Corp now owns 77,031 shares of the medical technology company’s stock valued at $10,141,000 after buying an additional 471 shares during the last quarter. Finally, Pensionfund DSM Netherlands purchased a new position in Stryker Corporation during the first quarter valued at $4,002,000. 73.79% of the stock is currently owned by institutional investors and hedge funds.

Stryker Corporation (NYSE:SYK) traded down 0.74% during mid-day trading on Friday, reaching $144.29. 1,673,285 shares of the company’s stock traded hands. The firm’s 50-day moving average price is $144.61 and its 200 day moving average price is $136.38. The firm has a market cap of $53.97 billion, a price-to-earnings ratio of 32.21 and a beta of 0.80. Stryker Corporation has a one year low of $106.48 and a one year high of $148.84.

Stryker Corporation (NYSE:SYK) last posted its earnings results on Thursday, July 27th. The medical technology company reported $1.53 earnings per share for the quarter, topping analysts’ consensus estimates of $1.51 by $0.02. Stryker Corporation had a net margin of 14.22% and a return on equity of 24.26%. The firm had revenue of $3.01 billion for the quarter, compared to the consensus estimate of $2.98 billion. During the same period in the previous year, the firm posted $1.39 EPS. The business’s quarterly revenue was up 6.1% on a year-over-year basis. On average, equities analysts forecast that Stryker Corporation will post $6.50 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, October 31st. Investors of record on Friday, September 29th will be paid a dividend of $0.425 per share. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $1.70 dividend on an annualized basis and a dividend yield of 1.18%. Stryker Corporation’s dividend payout ratio is presently 37.95%.

SYK has been the topic of several research analyst reports. BMO Capital Markets reaffirmed a “hold” rating and issued a $140.00 price target on shares of Stryker Corporation in a report on Tuesday, July 11th. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Stryker Corporation in a report on Monday, June 19th. Citigroup Inc. upped their price target on shares of Stryker Corporation from $114.00 to $125.00 and gave the stock a “sell” rating in a report on Friday, June 9th. Cantor Fitzgerald initiated coverage on shares of Stryker Corporation in a report on Thursday, June 29th. They issued a “neutral” rating and a $153.00 price target on the stock. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $160.00 price target (up previously from $155.00) on shares of Stryker Corporation in a report on Monday, July 10th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the stock. Stryker Corporation presently has an average rating of “Hold” and an average target price of $144.03.

In related news, insider Lonny J. Carpenter sold 5,000 shares of Stryker Corporation stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $146.36, for a total transaction of $731,800.00. Following the completion of the transaction, the insider now directly owns 88,207 shares of the company’s stock, valued at approximately $12,909,976.52. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Graham A. Mclean sold 1,124 shares of Stryker Corporation stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $146.26, for a total transaction of $164,396.24. Following the transaction, the insider now directly owns 8,983 shares of the company’s stock, valued at $1,313,853.58. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 32,810 shares of company stock valued at $4,754,958. 7.40% of the stock is owned by corporate insiders.

About Stryker Corporation

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.